Alfacalcidol is a nontoxic, effective treatment of follicular small-cleaved cell lymphoma (original) (raw)

Abstract

Thirty-four patients with progressive low grade non-Hodgkin's lymphoma were treated with 1 microgram oral alfacalcidol daily. Complete response was seen in four patients and a partial response in four patients with an overall response rate of 24%. Median duration of response was 14 months. Disease stabilised in ten other patients (29%) and 16 patients (47%) had tumour progression. In the sub-group of patients with follicular, small-cleaved cell-lymphoma the overall response to treatment was 29%. Apart from one patient who had a mild transitory elevation of serum calcium there was no recorded toxicity from alfacidol. These results indicate that alfacalcidol has significant antitumour activity in patients with low grade non-Hodgkin's lymphoma of the follicular, small-cleaved cell type.

Access options

Subscribe to this journal

Receive 24 print issues and online access

$259.00 per year

only $10.79 per issue

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Glasgow Royal Infirmary, UK
    V Raina

Authors

  1. V Raina
  2. D Cunningham
  3. N Gilchrist
  4. M Soukop

Rights and permissions

About this article

Cite this article

Raina, V., Cunningham, D., Gilchrist, N. et al. Alfacalcidol is a nontoxic, effective treatment of follicular small-cleaved cell lymphoma.Br J Cancer 63, 463–465 (1991). https://doi.org/10.1038/bjc.1991.108

Download citation

This article is cited by